Magnetic Coagulometry: Towards a New Nanotechnological Tool for Monitoring Coagulation in Human Whole Blood

Overview

Journal Nanoscale

Specialty Biotechnology

Date 2024 Jan 29

PMID 38285061

Authors

Antonio Santana-Otero

Alan Harper

Neil Telling

Daniel Ortega

David Cabrera

Affiliations

Soon will be listed here.

Abstract

Blood clotting disorders consisting of unwanted blood clot formation or excessive bleeding are some of the main causes of death worldwide. However, there are significant limitations in the current methods used to clinically monitor the dynamics of clot formation in human whole blood . Here a new magnetic coagulometry platform for testing coagulation is described. This platform exploits the sensitivity of the out-of-phase component of alternating current (AC) magnetic susceptibility ('') to variations in mobility and agglomeration of magnetic nanoparticles when trapped during blood clot formation. By labelling human whole blood with magnetic nanoparticles, the out-of-phase component of AC magnetic susceptibility shows that the dynamics of blood clot formation correlates with a decrease in the out-of-phase component '' over time activation of coagulation. This is caused by a rapid immobilisation of nanoparticles upon blood coagulation and compaction. In contrast, this rapid fall in the out-of-phase component '' is significantly slowed down when blood is pre-treated with three different anticoagulant drugs. Remarkably, the system showed sensitivity towards the effect of clinically used direct oral anticoagulation (DOAC) drugs in whole blood coagulation, in contrast to the inability of clinical routine tests prothrombin time (PT) and partial thromboplastin time (PTT) to efficiently monitor this effect. Translation of this nanomagnetic approach into clinic can provide a superior method for monitoring blood coagulation and improve the efficiency of the current diagnostic techniques.

References

Zhang X, Jin Q, Kong D, Pan C, Zhang X, Zhou D . Clinical outcomes of bivalirudin versus heparin in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion. Ann Transl Med. 2021; 9(8):629. PMC: 8106030. DOI: 10.21037/atm-20-4755. View

Peterson P, Hayes T, Arkin C, Bovill E, Fairweather R, Rock Jr W . The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg. 1998; 133(2):134-9. DOI: 10.1001/archsurg.133.2.134. View

Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W . Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013; . DOI: 10.1111/jth.12149. View

Soukup D, Moise S, Cespedes E, Dobson J, Telling N . In situ measurement of magnetization relaxation of internalized nanoparticles in live cells. ACS Nano. 2015; 9(1):231-40. DOI: 10.1021/nn503888j. View

Yau J, Teoh H, Verma S . Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015; 15:130. PMC: 4617895. DOI: 10.1186/s12872-015-0124-z. View

OHara J, Hughes D, Camp C, Burke T, Carroll L, Garcia Diego D . The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017; 12(1):106. PMC: 5452407. DOI: 10.1186/s13023-017-0660-y. View

Cabrera D, Walker K, Moise S, Telling N, Harper A . Controlling human platelet activation with calcium-binding nanoparticles. Nano Res. 2021; 13(10):2697-2705. PMC: 7116604. DOI: 10.1007/s12274-020-2912-8. View

Duewell B, Briski M, Feih J, Rinka J, Tawil J . Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia. J Pharm Pract. 2019; 34(4):529-534. DOI: 10.1177/0897190019882866. View

Samama M, Contant G, Spiro T, Perzborn E, Le Flem L, Guinet C . Laboratory assessment of rivaroxaban: a review. Thromb J. 2013; 11(1):11. PMC: 3726412. DOI: 10.1186/1477-9560-11-11. View

10.

Heestermans M, Naudin C, Mailer R, Konrath S, Klaetschke K, Jamsa A . Identification of the factor XII contact activation site enables sensitive coagulation diagnostics. Nat Commun. 2021; 12(1):5596. PMC: 8458485. DOI: 10.1038/s41467-021-25888-7. View

11.

Signorelli S, Scuto S, Marino E, Giusti M, Xourafa A, Gaudio A . Anticoagulants and Osteoporosis. Int J Mol Sci. 2019; 20(21). PMC: 6862478. DOI: 10.3390/ijms20215275. View

12.

Baglin T, Keeling D, Kitchen S . Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2012; 159(4):427-9. DOI: 10.1111/bjh.12052. View

13.

Schafer A, Levine M, Konkle B, Kearon C . Thrombotic disorders: diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2003; :520-39. DOI: 10.1182/asheducation-2003.1.520. View

14.

Kam P, Kaur N, Thong C . Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia. 2005; 60(6):565-74. DOI: 10.1111/j.1365-2044.2005.04192.x. View

15.

Adcock D, Gosselin R . Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb Res. 2015; 136(1):7-12. DOI: 10.1016/j.thromres.2015.05.001. View

16.

Michelson A, Bhatt D . How I use laboratory monitoring of antiplatelet therapy. Blood. 2017; 130(6):713-721. DOI: 10.1182/blood-2017-03-742338. View

17.

Wikkelso A, Wetterslev J, Moller A, Afshari A . Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2017; 72(4):519-531. DOI: 10.1111/anae.13765. View

18.

Yun S, Sim E, Goh R, Park J, Han J . Platelet Activation: The Mechanisms and Potential Biomarkers. Biomed Res Int. 2016; 2016:9060143. PMC: 4925965. DOI: 10.1155/2016/9060143. View

19.

Eikelboom J, Hirsh J, Spencer F, Baglin T, Weitz J . Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e89S-e119S. PMC: 3278069. DOI: 10.1378/chest.11-2293. View

20.

Cespedes E, Byrne J, Farrow N, Moise S, Coker V, Bencsik M . Bacterially synthesized ferrite nanoparticles for magnetic hyperthermia applications. Nanoscale. 2014; 6(21):12958-70. DOI: 10.1039/c4nr03004d. View